Literature DB >> 11248074

Site-specific mutations in the mature form of human IL-18 with enhanced biological activity and decreased neutralization by IL-18 binding protein.

S H Kim1, T Azam, D Y Yoon, L L Reznikov, D Novick, M Rubinstein, C A Dinarello.   

Abstract

IL-18 can be considered a proinflammatory cytokine mediating disease as well as an immunostimulatory cytokine that is important for host defense against infection and cancer. The high-affinity, constitutively expressed, and circulating IL-18 binding protein (IL-18BP), which competes with cell surface receptors for IL-18 and neutralizes IL-18 activity, may act as a natural antiinflammatory as well as immunosuppressive molecule. In the present studies, the IL-18 precursor caspase-1 cleavage site was changed to a factor Xa site, and, after expression in Escherichia coli, mature IL-18 was generated by factor Xa cleavage. Mature IL-18 generated by factor Xa cleavage was fully active. Single point mutations in the mature IL-18 peptide were made, and the biological activities of the wild-type (WT) IL-18 were compared with those of the mutants. Mutants E42A and K89A exhibited 2-fold increased activity compared with WT IL-18. A double mutant, E42A plus K89A, exhibited 4-fold greater activity. Unexpectedly, IL-18BP failed to neutralize the double mutant E42A plus K89A compared with WT IL-18. The K89A mutant was intermediate in being neutralized by IL-18BP, whereas neutralization of the E42A mutant was comparable to that in the WT IL-18. The identification of E42 and K89 in the mature IL-18 peptide is consistent with previous modeling studies of IL-18 binding to IL-18BP and explains the unusually high affinity of IL-18BP for IL-18.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11248074      PMCID: PMC30649          DOI: 10.1073/pnas.051634098

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  25 in total

1.  Cancer immunotherapy with alloreactive lymphocytes.

Authors:  S Slavin
Journal:  N Engl J Med       Date:  2000-09-14       Impact factor: 91.245

2.  Production of a biologically active human interleukin 18 requires its prior synthesis as PRO-IL-18.

Authors:  B Liu; D Novick; S H Kim; M Rubinstein
Journal:  Cytokine       Date:  2000-10       Impact factor: 3.861

Review 3.  Immunotherapy of hematologic malignancies and metastatic solid tumors in experimental animals and man.

Authors:  S Slavin; R Or; T Prighozina; O Gurevitch; M Aker; S Panighari; M Shapira; A Nagler
Journal:  Bone Marrow Transplant       Date:  2000-05       Impact factor: 5.483

4.  Structural requirements of six naturally occurring isoforms of the IL-18 binding protein to inhibit IL-18.

Authors:  S H Kim; M Eisenstein; L Reznikov; G Fantuzzi; D Novick; M Rubinstein; C A Dinarello
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-01       Impact factor: 11.205

5.  A poxvirus protein that binds to and inactivates IL-18, and inhibits NK cell response.

Authors:  T L Born; L A Morrison; D J Esteban; T VandenBos; L G Thebeau; N Chen; M K Spriggs; J E Sims; R M Buller
Journal:  J Immunol       Date:  2000-03-15       Impact factor: 5.422

6.  Interleukin-18 and the costimulatory molecule B7-1 have a synergistic anti-tumor effect on murine melanoma; implication of combined immunotherapy for poorly immunogenic malignancy.

Authors:  D Cho; T G Kim; W Lee; Y I Hwang; H I Cho; H Han; O Kwon; D Kim; H Park; D Houh
Journal:  J Invest Dermatol       Date:  2000-05       Impact factor: 8.551

7.  IL-18 binding and inhibition of interferon gamma induction by human poxvirus-encoded proteins.

Authors:  Y Xiang; B Moss
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-28       Impact factor: 11.205

8.  Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation.

Authors:  R Childs; A Chernoff; N Contentin; E Bahceci; D Schrump; S Leitman; E J Read; J Tisdale; C Dunbar; W M Linehan; N S Young; A J Barrett
Journal:  N Engl J Med       Date:  2000-09-14       Impact factor: 91.245

9.  IL-18 receptors, their role in ligand binding and function: anti-IL-1RAcPL antibody, a potent antagonist of IL-18.

Authors:  R Debets; J C Timans; T Churakowa; S Zurawski; R de Waal Malefyt; K W Moore; J S Abrams; A O'Garra; J F Bazan; R A Kastelein
Journal:  J Immunol       Date:  2000-11-01       Impact factor: 5.422

10.  Elevation of serum interleukin-18 levels and activation of Kupffer cells in biliary atresia.

Authors:  N Urushihara; H Iwagaki; T Yagi; H Kohka; K Kobashi; Y Morimoto; T Yoshino; T Tanimoto; M Kurimoto; N Tanaka
Journal:  J Pediatr Surg       Date:  2000-03       Impact factor: 2.545

View more
  13 in total

1.  Variola virus IL-18 binding protein interacts with three human IL-18 residues that are part of a binding site for human IL-18 receptor alpha subunit.

Authors:  Xiangzhi Meng; Michael Leman; Yan Xiang
Journal:  Virology       Date:  2006-09-18       Impact factor: 3.616

2.  The interaction between IL-18 and IL-18 receptor limits the magnitude of protective immunity and enhances pathogenic responses following infection with intracellular bacteria.

Authors:  Purnima Ghose; Asim Q Ali; Rong Fang; Digna Forbes; Billy Ballard; Nahed Ismail
Journal:  J Immunol       Date:  2011-06-29       Impact factor: 5.422

3.  A complex of the IL-1 homologue IL-1F7b and IL-18-binding protein reduces IL-18 activity.

Authors:  Philip Bufler; Tania Azam; Fabia Gamboni-Robertson; Leonid L Reznikov; Sanjay Kumar; Charles A Dinarello; Soo-Hyun Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-15       Impact factor: 11.205

4.  A surface amebic cysteine proteinase inactivates interleukin-18.

Authors:  Xuchu Que; Soo-Hyun Kim; Mohammed Sajid; Lars Eckmann; Charles A Dinarello; James H McKerrow; Sharon L Reed
Journal:  Infect Immun       Date:  2003-03       Impact factor: 3.441

5.  Surface cysteine to serine substitutions in IL-18 reduce aggregation and enhance activity.

Authors:  Jirakrit Saetang; Niran Roongsawang; Surasak Sangkhathat; Supayang Piyawan Voravuthikunchai; Natnaree Sangkaew; Napat Prompat; Teerapol Srichana; Varomyalin Tipmanee
Journal:  PeerJ       Date:  2022-07-05       Impact factor: 3.061

6.  Tumor necrosis factor-alpha causes release of cytosolic interleukin-18 from human neutrophils.

Authors:  Christopher C Silliman; Marguerite R Kelher; Fabia Gamboni-Robertson; Christine Hamiel; Kelly M England; Charles A Dinarello; Travis H Wyman; Samina Y Khan; Nathan J D McLaughlin; Rachel S Bercovitz; Anirban Banerjee
Journal:  Am J Physiol Cell Physiol       Date:  2009-11-11       Impact factor: 4.249

7.  Use of recombinant Entamoeba histolytica cysteine proteinase 1 to identify a potent inhibitor of amebic invasion in a human colonic model.

Authors:  Samuel G Meléndez-López; Scott Herdman; Ken Hirata; Min-Ho Choi; Youngchool Choe; Charles Craik; Conor R Caffrey; Elisabeth Hansell; Bibiana Chávez-Munguía; Yen Ting Chen; William R Roush; James McKerrow; Lars Eckmann; Jianhua Guo; Samuel L Stanley; Sharon L Reed
Journal:  Eukaryot Cell       Date:  2007-05-18

8.  Identification of the most active interleukin-32 isoform.

Authors:  Ji-Da Choi; Su-Young Bae; Jae-Woo Hong; Tania Azam; Charles A Dinarello; Erk Her; Whan-Soo Choi; Bo-Kyung Kim; Chang-Kwon Lee; Do-Young Yoon; Sun-Jong Kim; Soo-Hyun Kim
Journal:  Immunology       Date:  2008-09-02       Impact factor: 7.397

9.  Structural basis of human IL-18 sequestration by the decoy receptor IL-18 binding protein in inflammation and tumor immunity.

Authors:  Sam Detry; Julie Andries; Yehudi Bloch; Cem Gabay; Danielle M Clancy; Savvas N Savvides
Journal:  J Biol Chem       Date:  2022-04-06       Impact factor: 5.486

10.  The structural basis for receptor recognition of human interleukin-18.

Authors:  Naotaka Tsutsumi; Takeshi Kimura; Kyohei Arita; Mariko Ariyoshi; Hidenori Ohnishi; Takahiro Yamamoto; Xiaobing Zuo; Katsumi Maenaka; Enoch Y Park; Naomi Kondo; Masahiro Shirakawa; Hidehito Tochio; Zenichiro Kato
Journal:  Nat Commun       Date:  2014-12-15       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.